文献速递前列腺癌

进展性前列腺癌患者开始多西他赛联合或不联合恩扎卢胺治疗时的液体活检:PRESIDE 3b 期试验的生物标志物研究

Liquid Biopsy in Progressing Prostate Cancer Patients Starting Docetaxel with or Without Enzalutamide: A Biomarker Study of the PRESIDE Phase 3b Trial.
PubMed 文献 · Eur Urol Oncol · 2024-09-11

PRESIDE 3b 期试验生物标志物亚组纳入 157 例开始多西他赛联合恩扎卢胺/安慰剂的转移性去势抵抗性前列腺癌患者,分析循环肿瘤 DNA 与液体活检耐药标志物(血浆雄激素受体增益和/或表达 AR 剪接变异体 7 的循环肿瘤细胞)与无进展生存期的关联。多西他赛前检出 ctDNA 及 C2D1 时 ctDNA 持续/升高与更差 PFS 显著相关;耐药标志物阳性患者继续恩扎卢胺无获益,阴性患者显著获益。

要点

  • 多西他赛前检出 ctDNA 与更差 PFS 显著相关(8.1 vs 10.8 个月,HR=1.78,p=0.004)
  • C2D1 时 ctDNA 持续/升高与更差 PFS 显著相关(5.5 vs 10.9 个月,HR=1.95)
  • 耐药标志物阴性患者继续恩扎卢胺显著延长 PFS(HR=0.49),阳性患者无获益

核心结论

  • 液体活检可早期提示多西他赛无效,可能指导继续恩扎卢胺的患者选择,并发现细胞周期基因改变可能是 mCRPC 多西他赛耐药的潜在原因。

研究设计与样本

  • PRESIDE(NCT02288247)随机试验的生物标志物亚组研究,纳入同意参加并献血的多西他赛联合恩扎卢胺/安慰剂治疗前患者 N=157。
  • 连续血浆 DNA 样本采用前列腺癌定制下一代测序捕获 panel(PCF_SELECT)检测,循环肿瘤细胞采用 Epic Sciences 检测 AR-V7。
  • 计算 Cox 模型、Kaplan-Meier 及 18 个月限制性平均生存时间(RMST)。

主要发现

  • 多西他赛前检出 ctDNA 者 N=86(55%),PFS 8.1 vs 10.8 个月,HR=1.78,p=0.004。
  • C2D1 时 ctDNA 持续/升高者 N=35/134,PFS 5.5 vs 10.9 个月,HR=1.95,95%CI=1.15-3.30,p=0.019。
  • 液体活检耐药标志物阳性患者 N=62,继续恩扎卢胺联合多西他赛无获益(HR=0.78,95%CI=0.41-1.48,p=0.44;RMST 7.9 vs 7.1 个月,p=0.50)。
  • 耐药标志物阴性患者 N=87,PFS 显著延长(HR=0.49,95%CI=0.29-0.82,p=0.006;RMST 11.5 vs 8.9 个月,p=0.005)。
  • 8 例患者无法评估;探索性分析发现多西他赛进展时 CDK6/CDK4 拷贝数增益增加。

临床怎么用

  • 原文结论认为液体活检可早期提示多西他赛无效,可能指导继续恩扎卢胺的患者选择。
  • 原文患者摘要指出耐药标志物阴性患者继续恩扎卢胺联合多西他赛获益,阳性患者未获益。
  • 原文认为 CDK6/CDK4 改变可能支持测试靶向这些改变的特定药物。

局限性

  • 局限性包括 CTC-AR-V7 检出率相对较低。
  • 需要对总生存期影响进行验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: The PRESIDE (NCT02288247) randomized trial demonstrated prolonged progression-free survival (PFS) with continuing enzalutamide beyond progression in metastatic castration-resistant prostate cancer (mCRPC) patients starting docetaxel. This study aims to test the associations of PFS and circulating tumor DNA (ctDNA) prior to and after one cycle (cycle 2 day 1 [C2D1]) of docetaxel and with a liquid biopsy resistance biomarker (LBRB; plasma androgen receptor [AR] gain and/or circulating tumor cells [CTCs] expressing AR splice variant 7 [CTC-AR-V7]) prior to continuation of enzalutamide/placebo. METHODS: Patients consenting to the biomarker substudy and donating blood before starting docetaxel with enzalutamide/placebo (N = 157) were included. Sequential plasma DNA samples were characterized with a prostate-cancer bespoke next-generation-sequencing capture panel (PCF_SELECT), and CTCs were assessed for AR-V7 (Epic Sciences, San Diego, CA, USA). Cox models, Kaplan-Meier, and restricted mean survival time (RMST) at 18 mo were calculated. KEY FINDINGS AND LIMITATIONS: There was a significant association of worse PFS with pre-docetaxel ctDNA detection (N = 86 (55%), 8.1 vs 10.8 mo hazard ratio [HR] = 1.78, p = 0.004) or persistence/rise of ctDNA at C2D1 (N = 35/134, 5.5 vs 10.9 mo, HR = 1.95, 95% confidence interval [CI] = 1.15-3.30, p = 0.019). LBRB-positive patients (N = 62) had no benefit from continuing enzalutamide with docetaxel (HR = 0.78, 95% CI = 0.41-1.48, p = 0.44; RMST: 7.9 vs 7.1 mo, p = 0.50). Conversely, resistance biomarker-negative patients (N = 87) had significantly prolonged PFS (HR = 0.49, 95% CI = 0.29-0.82, p = 0.006; RMST: 11.5 vs 8.9 mo, p = 0.005). Eight patients were unevaluable. An exploratory analysis identified increased copy-number gains (CDK6/CDK4) at progression on docetaxel. Limitations included relatively low detection of CTC-AR-V7. Validation of impact on overall survival is required. CONCLUSIONS AND CLINICAL IMPLICATIONS: Liquid biopsy gives an early indication of docetaxel futility, could guide patient selection for continuing enzalutamide, and identifies cell cycle gene alterations as a potential cause of docetaxel resistance in mCRPC. PATIENT SUMMARY: In the PRESIDE biomarker study, we found that detecting circulating tumor DNA in plasma after starting treatment with docetaxel (chemotherapy) for metastatic prostate cancer resistant to androgen deprivation therapy can predict early how long patients will take to respond to treatment. Patients negative for a liquid biopsy resistance biomarker (based on the status of androgen receptor (AR) gene and AR splice variant 7 in circulating tumor cells) benefit from continuing enzalutamide in combination with docetaxel, while patients positive for the resistance biomarker did not. Additionally, we identified alterations in the cell cycle genes CDK6 and CDK4 as a potential genetic cause of resistance to docetaxel, which may support testing of specific drugs targeting these alterations.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Ruiz-Vico M, Wetterskog D, Orlando F, et al. Liquid Biopsy in Progressing Prostate Cancer Patients Starting Docetaxel with or Without Enzalutamide: A Biomarker Study of the PRESIDE Phase 3b Trial. Eur Urol Oncol. 2024. PMID: 39261236. doi:10.1016/j.euo.2024.08.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。